These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 26668994)

  • 1. [Progress in the biomarker discovery for drug-induced liver injury].
    He LY; Guo YX; Li C; Deng Y; Zhang QZ; Peng WX
    Yao Xue Xue Bao; 2015 Aug; 50(8):959-65. PubMed ID: 26668994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of urine proteomics for biomarker discovery in drug-induced liver injury.
    van Swelm RP; Kramers C; Masereeuw R; Russel FG
    Crit Rev Toxicol; 2014 Nov; 44(10):823-41. PubMed ID: 25264586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomic approaches in the discovery of potential urinary biomarkers of drug-induced liver injury (DILI).
    Araújo AM; Carvalho M; Carvalho F; Bastos ML; Guedes de Pinho P
    Crit Rev Toxicol; 2017 Sep; 47(8):633-649. PubMed ID: 28436314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers for the diagnosis and management of drug-induced liver injury.
    Watkins PB
    Semin Liver Dis; 2009 Nov; 29(4):393-9. PubMed ID: 19826973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of cytokeratin-18 as a biomarker for drug-induced liver injury.
    Korver S; Bowen J; Pearson K; Gonzalez RJ; French N; Park K; Jenkins R; Goldring C
    Arch Toxicol; 2021 Nov; 95(11):3435-3448. PubMed ID: 34322741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for drug-induced liver injury.
    Shi Q; Hong H; Senior J; Tong W
    Expert Rev Gastroenterol Hepatol; 2010 Apr; 4(2):225-34. PubMed ID: 20350268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting idiosyncratic drug-induced liver injury: some recent advances.
    Chen M; Borlak J; Tong W
    Expert Rev Gastroenterol Hepatol; 2014 Sep; 8(7):721-3. PubMed ID: 24857265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latest advances in diagnosing and predicting DILI: what was new in 2017?
    Barnhill MS; Real M; Lewis JH
    Expert Rev Gastroenterol Hepatol; 2018 Oct; 12(10):1033-1043. PubMed ID: 30111182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.
    Lo Re V; Haynes K; Forde KA; Goldberg DS; Lewis JD; Carbonari DM; Leidl KB; Reddy KR; Nezamzadeh MS; Roy J; Sha D; Marks AR; De Boer J; Schneider JL; Strom BL; Corley DA
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2360-8. PubMed ID: 26122767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation.
    McGill MR; Jaeschke H
    Expert Rev Mol Diagn; 2018 Sep; 18(9):797-807. PubMed ID: 30080986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug-induced liver injury and drug development: industry perspective.
    Regev A
    Semin Liver Dis; 2014 May; 34(2):227-39. PubMed ID: 24879986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of blood biomarkers for drug-induced liver injury: an evaluation of their potential for risk assessment and diagnostics.
    Amacher DE; Schomaker SJ; Aubrecht J
    Mol Diagn Ther; 2013 Dec; 17(6):343-54. PubMed ID: 23868512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Clinical Biomarkers for Drug-Induced Liver Injury.
    Chen Y; Guan S; Guan Y; Tang S; Zhou Y; Wang X; Bi H; Huang M
    Drug Metab Dispos; 2022 May; 50(5):671-684. PubMed ID: 34903588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-silico approach for drug induced liver injury prediction: Recent advances.
    Saini N; Bakshi S; Sharma S
    Toxicol Lett; 2018 Oct; 295():288-295. PubMed ID: 29981923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transformation in biomarker detection and management of drug-induced liver injury.
    Church RJ; Watkins PB
    Liver Int; 2017 Nov; 37(11):1582-1590. PubMed ID: 28386997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury.
    Howell LS; Ireland L; Park BK; Goldring CE
    Expert Rev Mol Diagn; 2018 Jan; 18(1):47-54. PubMed ID: 29235390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A longitudinal assessment of miR-122 and GLDH as biomarkers of drug-induced liver injury in the rat.
    Thulin P; Hornby RJ; Auli M; Nordahl G; Antoine DJ; Starkey Lewis P; Goldring CE; Park BK; Prats N; Glinghammar B; Schuppe-Koistinen I
    Biomarkers; 2017 Jul; 22(5):461-469. PubMed ID: 27978773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latest advances in predicting DILI in human subjects: focus on biomarkers.
    Hawkins MT; Lewis JH
    Expert Opin Drug Metab Toxicol; 2012 Dec; 8(12):1521-30. PubMed ID: 22998122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans?
    Zhang M; Chen M; Tong W
    Chem Res Toxicol; 2012 Jan; 25(1):122-9. PubMed ID: 22122743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hopes and challenges in using miRNAs as translational biomarkers for drug-induced liver injury.
    Shi Q; Yang X; Mendrick DL
    Biomark Med; 2013 Apr; 7(2):307-15. PubMed ID: 23547824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.